1 |
Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. J Am Acad Dermatol 2007;56:181-200.
DOI
ScienceOn
|
2 |
Downey A, Jackson C, Harun N, Cooper A. Toxic epidermal necrolysis: review of pathogenesis and management. J Am Acad Dermatol 2012;66:995-1003.
DOI
ScienceOn
|
3 |
Harr T, French LE. Stevens-Johnson syndrome and toxic epidermal necrolysis. Chem Immunol Allergy 2012;97:149-66.
DOI
ScienceOn
|
4 |
Kim DW, Jung DE, Koo JW. Steroid and enalapril therapy-possible cause of toxic epidermal necrolysis. Korean J Pediatr 2006;49:332-6.
DOI
|
5 |
Chang CC, Shiah IS, Chang HA, Huang SY. Toxic epidermal necrolysis with combination lamotrigine and valproate in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:147-50.
DOI
ScienceOn
|
6 |
Hirsch LJ, Weintraub DB, Buchsbaum R, Spencer HT, Straka T, Hager M, et al. Predictors of Lamotrigine-associated rash. Epilepsia 2006;47:318-22.
DOI
ScienceOn
|
7 |
Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis 2010;5:39.
DOI
ScienceOn
|
8 |
Joseph G. Morelli. Vesiculobullous disorders. In: Kliegman RM, Stanton BF, St. Geme JW III, Schor NF, Behrman RE, editors. Nelsn textbook of pediatrics. 19th ed. Philadelphia: Elsevier Saunders, 2011:2243.
|
9 |
Abood GJ, Nickoloff BJ, Gamelli RL. Treatment strategies in toxic epidermal necrolysis syndrome: where are we at? J Burn Care Res 2008;29:269-76.
DOI
|
10 |
Gerull R, Nelle M, Schaible T. Toxic epidermal necrolysis and Stevens-Johnson syndrome: a review. Crit Care Med 2011;39:1521-32.
DOI
ScienceOn
|
11 |
Warnock JK, Morris DW. Adverse cutaneous reactions to mood stabilizers. Am J Clin Dermatol 2003;4:21-30.
DOI
ScienceOn
|
12 |
Kim KJ, Lee DP, Suh HS, Lee MW, Choi JH, Moon KC, et al. Toxic epidermal necrolysis: analysis of clinical course and SCORTENbased comparison of mortality rate and treatment modalities in Korean patients. Acta Derm Venereol 2005;85:497-502.
|
13 |
Lissia M, Mulas P, Bulla A, Rubino C. Toxic epidermal necrolysis (Lyell's disease). Burns 2010;36:152-63.
DOI
ScienceOn
|
14 |
Ruetter A, Luger TA. Efficacy and safety of intravenous immunoglobulin for immune-mediated skin disease: current view. Am J Clin Dermatol 2004;5:153-60.
DOI
ScienceOn
|
15 |
Li LM, Russo M, O'Donoghue MF, Duncan JS, Sander JW. Allergic skin rash with lamotrigine and concomitant valproate therapy: evidence for an increased risk. Arq Neuropsiquiatr 1996;54:47-9.
DOI
|
16 |
Schlienger RG, Shapiro LE, Shear NH. Lamotrigine-induced severe cutaneous adverse reactions. Epilepsia 1998;39 Suppl 7:S22-6.
DOI
ScienceOn
|
17 |
Guberman AH, Besag FM, Brodie MJ, Dooley JM, Duchowny MS, Pellock JM, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999;40:985-91.
DOI
ScienceOn
|